Search

Materials-based drug delivery approaches have garnered substantial attention in recent years due to their potential to revolutionize pharmaceutical interventions. This abstract provides a concise overview of recent advancements and future prospects in this rapidly evolving field. Materials such as nanoparticles, liposomes, polymers, and hydrogels have emerged as versatile carriers for drug delivery. These materials facilitate precise control over drug release kinetics, enabling targeted and sustained therapeutic effects. Smart materials with responsiveness to external stimuli or physiological conditions have further enhanced drug delivery precision. Personalized medicine approaches are gaining traction, tailoring drug delivery systems to individual patient profiles and needs. The horizon for materials-based drug delivery is bright. Ongoing research is focused on refining material design, streamlining production processes, and ensuring safety profiles. Collaborative efforts among researchers, clinicians, and industry stakeholders are crucial for translating these advancements into clinical practice. Additionally, the convergence of drug delivery with diagnostics and imaging holds immense potential for personalized and efficient healthcare solutions. As materials-based drug delivery continues to evolve, it stands poised to reshape the landscape of pharmaceuticals, offering the promise of more effective and patient-centered therapies for a wide range of medical conditions.

Nanoparticles are attractive therapeutic tools due to their distinctive characteristics, including more accurate drug delivery, improved bioavailability, and enhanced targeted therapy. This review offers a comprehensive analysis of the therapeutic potentials of cutting-edge nanoparticles as demonstrated in human clinical trials, based on empirical evidence. Through systematic searches of major scientific databases, relevant studies published up to March 2024 were included, focusing on clinical trials utilizing advanced nanoparticles for therapeutic purposes. The review discusses the diverse applications of nanoparticles in oncology, infectious diseases, neurology, and other medical fields. Additionally, it scrutinizes the safety profiles, efficacy outcomes, and challenges associated with nanoparticle-based therapies. The findings underscore significant progress in translating nanoparticle research into clinical practice and highlight the potential of these innovative platforms to revolutionize medical treatments. This review contributes valuable insights into the growing field of nanoparticle-based therapeutics, fostering a deeper understanding of their clinical applications and implications in medical practice. [ABSTRACT FROM AUTHOR]

Alzheimer's disease (AD) is a multifaceted neurodegenerative condition marked by gradual cognitive deterioration and the loss of neurons. While conventional bulk RNA sequencing techniques have shed light on AD pathology, they frequently obscure the cellular diversity within brain tissues. The advent of single-cell RNA sequencing (scRNA-seq) has transformed our capability to analyze the cellular composition of AD, allowing for the detection of unique cell populations, rare cell types, and gene expression alterations at an individual cell level. This review examines the use of scRNA-seq in AD research, focusing on its contributions to understanding cellular diversity, disease progression, and potential therapeutic targets. We discuss key technological innovations, data analysis techniques, and challenges associated with scRNA-seq in studying AD. Furthermore, we highlight recent studies that have utilized scRNA-seq to identify novel biomarkers, uncover disease-associated pathways, and elucidate the role of non-neuronal cells, such as microglia and astrocytes, in AD pathogenesis. By providing a comprehensive overview of advancements in scRNA-seq for unraveling cellular heterogeneity in AD, this review highlights the transformative impact of scRNA-seq on our comprehension of disease mechanisms and the creation of targeted treatments. [Display omitted] [ABSTRACT FROM AUTHOR]

Alzheimer's disease (AD) stands as a formidable challenge in modern medicine, characterized by progressive neurodegeneration, cognitive decline, and memory impairment. Despite extensive research, effective therapeutic strategies remain elusive. The antioxidant, anti-inflammatory, and neuroprotective properties of curcumin, found in turmeric, have demonstrated promise. The poor bioavailability and rapid systemic clearance of this drug limit its clinical application. This comprehensive review explores the potential of curcumin-loaded polymeric nanomaterials as an innovative therapeutic avenue for AD. It delves into the preparation and characteristics of diverse polymeric nanomaterial platforms, including liposomes, micelles, dendrimers, and polymeric nanoparticles. Emphasis is placed on how these platforms enhance curcumin's bioavailability and enable targeted delivery to the brain, addressing critical challenges in AD treatment. Mechanistic insights reveal how these nanomaterials modulate key AD pathological processes, including amyloid-beta aggregation, tau phosphorylation, oxidative stress, and neuroinflammation. The review also highlighted the preclinical studies demonstrate reduced amyloid-beta plaques and neuroinflammation, alongside improved cognitive function, while clinical trials show promise in enhancing curcumin's bioavailability and efficacy in AD. Additionally, it addresses the challenges of clinical translation, such as regulatory issues, large-scale production, and long-term stability. By synthesizing recent advancements, this review underscores the potential of curcumin-loaded polymeric nanomaterials to offer a novel and effective therapeutic approach for AD, aiming to guide future research and development in this field. [Display omitted] • Curcumin-loaded nanomaterials improve bioavailability for Alzheimer's treatment. • Polymeric platforms enable targeted brain delivery of curcumin in AD therapy. • Nanomaterials modulate amyloid-beta aggregation and tau phosphorylation. • Review highlights preclinical and clinical efficacy of curcumin nanomaterials. • Challenges in clinical translation of curcumin-loaded nanomaterials are discussed. [ABSTRACT FROM AUTHOR]